1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. Japan >
  5. Chugai Acquires Renalys Pharma

M&A Deal Summary

Chugai Acquires Renalys Pharma

On October 24, 2025, Chugai acquired life science company Renalys Pharma

Acquisition Highlights
  • This is Chugai’s 1st transaction in the Life Science sector.
  • This is Chugai’s 1st transaction in Japan.

M&A Deal Summary
Date 2025-10-24
Target Renalys Pharma
Sector Life Science
Buyer(s) Chugai
Deal Type Add-on Acquisition

Target

Renalys Pharma

Tokyo, Japan
Renalys Pharma is a late-stage clinical biopharmaceutical company focused on developing innovative therapeutics targeting unmet needs in the management of renal disease for Japanese and Asian patients. Renalys Pharma is based in Tokyo.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Chugai

Tokyo, Japan
Category Company
Sector Life Science
Revenue 1.17T JPY (2024)
DESCRIPTION

Chugai is a research-based pharmaceutical company with drug discovery capabilities, including proprietary antibody engineering technologies. The company creates innovative pharmaceutical products that may satisfy unmet medical needs. Chugai is based in Tokyo.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
Country: Japan M&A 1 of 1
Year: 2025 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal